HIV-1 derived peptides fused to HBsAg affect its immunogenicity

Virus Research

Volumn 146, Issue 1-2, 2009, Pages 107-114

  Cervantes Gonzalez, Minerva ^a   Kostrzak, Anna ^a,b,c   Guetard, Denise ^a   Pniewski, Tomasz ^b   Sala, Monica ^a  

^a INSTITUT PASTEUR   (France)

^b INSTITUTE OF PLANT GENETICS   (Poland)

^c INRA Institut National de la Recherche Agronomique   (France)

Author keywords

HBsAg; HBV; HIV 1; Virus sized vaccine delivery system; VLPs

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; VIRUS GENE; VIRUS LIKE AGENT;

AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HIV-1; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTERFERON-GAMMA; LYMPHOCYTE SUBSETS; MICE; MOLECULAR SEQUENCE DATA; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; VACCINES, DNA; VACCINES, SYNTHETIC;

HEPATITIS B VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 70350396597     PISSN: 01681702     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virusres.2009.09.007     Document Type: Article

References (41)

1. Baez-Astua A., Herraez-Hernandez E., Garbi N., Pasolli H.A., Juarez V., Zur Hausen H., and Cid-Arregui A. Low-dose adenovirus vaccine encoding chimeric hepatitis B virus surface antigen-human papillomavirus type 16 E7 proteins induces enhanced E7-specific antibody and cytotoxic T-cell responses. J. Virol. 79 20 (2005) 12807-12817
2. Benhamou Y. Hepatitis B in the HIV-coinfected patient. J. Acquir. Immune Defic. Syndr. 45 Suppl. 2 (2007) S57-S65 (discussion S66-S67)
3. Berkower I., Raymond M., Muller J., Spadaccini A., and Aberdeen A. Assembly, structure, and antigenic properties of virus-like particles rich in HIV-1 envelope gp120. Virology 321 1 (2004) 75-86
4. Beyer T., Herrmann M., Reiser C., Bertling W., and Hess J. Bacterial carriers and virus-like-particles as antigen delivery devices: role of dendritic cells in antigen presentation. Curr. Drug Targets Infect. Disord. 1 3 (2001) 287-302
5. Boisgerault F., Moron G., and Leclerc C. Virus-like particles: a new family of delivery systems. Expert Rev. Vaccines 1 1 (2002) 101-109
6. Brocke P., Schaefer S., Melber K., Jenzelewski V., Müller F., Dahlems U., Bartelsen O., Park K.-N., Janowicz Z.A., and Gellissen G. Recombinant hepatitis B vaccines: disease characterization and vaccine production. In: Gellissen I.G. (Ed). Production of Recombinant Proteins. Novel Microbial and Eukaryotic Systems (2005), VCH Verlag GmbH & Co KGaA, Wiley 319-359
7. Cheong W.S., Drummer H.E., and Netter H.J. Delivery of a foreign epitope by sharing amino acid residues with the carrier matrix. J. Virol. Methods 158 1-2 (2009) 35-40
8. Davis H.L., Brazolot Millan C.L., Mancini M., McCluskie M.J., Hadchouel M., Comanita L., Tiollais P., Whalen R.G., and Michel M.L. DNA-based immunization against hepatitis B surface antigen (HBsAg) in normal and HBsAg-transgenic mice. Vaccine 15 8 (1997) 849-852
9. Davis H.L., Millan C.L., and Watkins S.C. Immune-mediated destruction of transfected muscle fibers after direct gene transfer with antigen-expressing plasmid DNA. Gene Ther. 4 3 (1997) 181-188
10. Delpeyroux F., Chenciner N., Lim A., Malpiece Y., Blondel B., Crainic R., van der Werf S., and Streeck R.E. A poliovirus neutralization epitope expressed on hybrid hepatitis B surface antigen particles. Science 233 4762 (1986) 472-475
11. El Kholy S., Riedl P., Kwissa M., Reimann J., and Schirmbeck R. Selective expression of immunogenic, virus-like particle-derived antibody-binding epitopes. Intervirology 45 4-6 (2002) 251-259
12. Firat H., Tourdot S., Ureta-Vidal A., Scardino A., Suhrbier A., Buseyne F., Riviere Y., Danos O., Michel M.L., Kosmatopoulos K., and Lemonnier F.A. Design of a polyepitope construct for the induction of HLA-A0201-restricted HIV 1-specific CTL responses using HLA-A*0201 transgenic, H-2 class I KO mice. Eur. J. Immunol. 31 10 (2001) 3064-3074
13. Greco R., Michel M., Guetard D., Cervantes-Gonzalez M., Pelucchi N., Wain-Hobson S., Sala F., and Sala M. Production of recombinant HIV-1/HBV virus-like particles in Nicotiana tabacum and Arabidopsis thaliana plants for a bivalent plant-based vaccine. Vaccine 25 49 (2007) 8228-8240
14. Guetard D., Greco R., Cervantes Gonzalez M., Celli S., Kostrzak A., Langlade-Demoyen P., Sala F., Wain-Hobson S., and Sala M. Immunogenicity and tolerance following HIV-1/HBV plant-based oral vaccine administration. Vaccine 26 35 (2008) 4477-4485
15. Heath W.R., and Carbone F.R. Cross-presentation, dendritic cells, tolerance and immunity. Annu. Rev. Immunol. 19 (2001) 47-64
16. Kirnbauer R., Booy F., Cheng N., Lowy D.R., and Schiller J.T. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl. Acad. Sci. U.S.A. 89 24 (1992) 12180-12184
17. Kostrzak A., Cervantes Gonzalez M., Guetard D., Devendra Bellary Nagaraju D., Wain-Hobson S., Tepfer D., Pniewski T., and Sala M. Oral administration of low doses of plant-based HBsAg induced antigen-specific IgAs and IgGs in mice, without increasing levels of regulatory T cells. Vaccine (2009) 10.1016/j.vaccine.2009.05.092
18. Kozak M. Pushing the limits of the scanning mechanism for initiation of translation. Gene 299 1-2 (2002) 1-34
19. Kuffova L., Netukova M., Duncan L., Porter A., Stockinger B., and Forrester J.V. Cross presentation of antigen on MHC class II via the draining lymph node after corneal transplantation in mice. J. Immunol. 180 3 (2008) 1353-1361
20. Liang A., Cao S., Han L., Yao Y., Moaeen-Ud-Din M., and Yang L. Construction and evaluation of the eukaryotic expression plasmid encoding two copies of somatostatin genes fused with hepatitis B surface antigen gene S. Vaccine 26 23 (2008) 2935-2941
21. Ly T.D., Servant-Delmas A., Bagot S., Gonzalo S., Ferey M.P., Ebel A., Dussaix E., Laperche S., and Roque-Afonso A.M. Sensitivities of four new commercial hepatitis B virus surface antigen (HBsAg) assays in detection of HBsAg mutant forms. J. Clin. Microbiol. 44 7 (2006) 2321-2326
22. Mancini M., Schlienger K., Tiollais P., and Michel M.L. Immunogenicity of hybrid hepatitis B surface antigen particles. Int. Rev. Immunol. 11 2 (1994) 143-151
23. Mangold C.M., Unckell F., Werr M., and Streeck R.E. Secretion and antigenicity of hepatitis B virus small envelope proteins lacking cysteines in the major antigenic region. Virology 211 2 (1995) 535-543
24. Mangold C.M., Unckell F., Werr M., and Streeck R.E. Analysis of intermolecular disulfide bonds and free sulfhydryl groups in hepatitis B surface antigen particles. Arch. Virol. 142 11 (1997) 2257-2267
25. Marsac D., Puaux A.-L., Riviere Y., and Michel M.L. In vivo induction of cellular and humoral immune response by hybrid DNA vectors encoding simian/human immunodeficiency virus/hepatitis B surface antigen virus particles in BALB/c and HLA-A2-transgenic mice. Immunobiology 210 5 (2005) 305-319
26. Michel M., Lone Y.C., Centlivre M., Roux P., Wain-Hobson S., and Sala M. Optimisation of secretion of recombinant HBsAg virus-like particles: Impact on the development of HIV-1/HBV bivalent vaccines. Vaccine 25 10 (2007) 1901-1911
27. Michel M.L., Davis H.L., Schleef M., Mancini M., Tiollais P., and Whalen R.G. DNA-mediated immunization to the hepatitis B surface antigen in mice: aspects of the humoral response mimic hepatitis B viral infection in humans. Proc. Natl. Acad. Sci. U.S.A. 92 12 (1995) 5307-5311
28. Michel M.L., Mancini M., Riviere Y., Dormont D., and Tiollais P. T- and B-lymphocyte responses to human immunodeficiency virus (HIV) type 1 in macaques immunized with hybrid HIV/hepatitis B surface antigen particles. J. Virol. 64 5 (1990) 2452-2455
29. Michel M.L., Mancini M., Sobczak E., Favier V., Guetard D., Bahraoui E.M., and Tiollais P. Induction of anti-human immunodeficiency virus (HIV) neutralizing antibodies in rabbits immunized with recombinant HIV-hepatitis B surface antigen particles. Proc. Natl. Acad. Sci. U.S.A. 85 21 (1988) 7957-7961
30. Mottram P.L., Leong D., Crimeen-Irwin B., Gloster S., Xiang S.D., Meanger J., Ghildyal R., Vardaxis N., and Plebanski M. Type 1 and 2 immunity following vaccination is influenced by nanoparticle size: formulation of a model vaccine for respiratory syncytial virus. Mol. Pharm. 4 1 (2007) 73-84
31. Mowat A.M. Dendritic cells and immune responses to orally administrated antigens. Vaccine 23 (2005) 1797-1799
32. Pajot A., Michel M.L., Fazilleau N., Pancre V., Auriault C., Ojcius D.M., Lemonnier F.A., and Lone Y.C. A mouse model of human adaptive immune functions: HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout mice. Eur. J. Immunol. 34 11 (2004) 3060-3069
33. Pajot A., Michel M.L., Mancini-Bourgine M., Ungeheuer M.N., Ojcius D.M., Deng Q., Lemonnier F.A., and Lone Y.C. Identification of novel HLA-DR1-restricted epitopes from the hepatitis B virus envelope protein in mice expressing HLA-DR1 and vaccinated human subjects. Microbes Infect. 8 12-13 (2006) 2783-2790
34. Phogat S., Svehla K., Tang M., Spadaccini A., Muller J., Mascola J., Berkower I., and Wyatt R. Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external region arrayed on hepatitis B surface antigen particles. Virology 373 1 (2008) 72-84
35. Pumpens P., Razanskas R., Pushko P., Renhof R., Gusars I., Skrastina D., Ose V., Borisova G., Sominskaya I., Petrovskis I., Jansons J., and Sasnauskas K. Evaluation of HBs, HBc, and frCP virus-like particles for expression of human papillomavirus 16 E7 oncoprotein epitopes. Intervirology 45 1 (2002) 24-32
36. Qian B., Shen H., Liang W., Guo X., Zhang C., Wang Y., Li G., Wu A., Cao K., and Zhang D. Immunogenicity of recombinant hepatitis B virus surface antigen fused with preS1 epitopes expressed in rice seeds. Transgenic Res. 17 4 (2008) 621-631
37. Roy P., and Noad R. Virus-like particles as a vaccine delivery system: myths and facts. Hum. Vaccin. 4 1 (2008) 5-12
38. Scheerlinck J.-P.Y., and Greenwood D.L.V. Virus-sized vaccine delivery systems. Drug Discov. Today 13 19/20 (2008) 882-887
39. Schlienger K., Mancini M., Riviere Y., Dormont D., Tiollais P., and Michel M.L. Human immunodeficiency virus type 1 major neutralizing determinant exposed on hepatitis B surface antigen particles is highly immunogenic in primates. J. Virol. 66 4 (1992) 2570-2576
40. Vietheer P.T., Boo I., Drummer H.E., and Netter H.J. Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies. Antivir. Ther. 12 4 (2007) 477-487
41. Yan M., Peng J., Jabbar I.A., Liu X., Filgueira L., Frazer I.H., and Thomas R. Despite differences between dendritic cells and Langerhans cells in the mechanism of papillomavirus-like particle antigen uptake, both cells cross-prime T cells. Virology 324 2 (2004) 297-310